WO2006046626A1 - 水溶性エラスチンとその製造方法及びそれを含む食品と医薬 - Google Patents
水溶性エラスチンとその製造方法及びそれを含む食品と医薬 Download PDFInfo
- Publication number
- WO2006046626A1 WO2006046626A1 PCT/JP2005/019751 JP2005019751W WO2006046626A1 WO 2006046626 A1 WO2006046626 A1 WO 2006046626A1 JP 2005019751 W JP2005019751 W JP 2005019751W WO 2006046626 A1 WO2006046626 A1 WO 2006046626A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- elastin
- water
- soluble
- molecular weight
- soluble elastin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to high purity low molecular weight water soluble elastin and high molecular weight water soluble elastin which can obtain water soluble elastin, a method for producing them, and food and pharmaceutical use of low molecular weight water soluble elastin .
- Elastin is a protein that is present together with collagen in the connective tissue of the dermis, ligaments, tendons, blood vessel walls and the like of the skin of animals, particularly mammals. Elastin usually exists as an insoluble protein in a three-dimensional network structure in vivo. It is widely known that water-soluble elastin can be obtained by hydrolyzing such elastin with acid or alkali or treating it with an enzyme. And since water-soluble elastin has the ability to hold a large amount of water, it is used as a cosmetic, especially as a moisturizer (eg, patent documents 1 to 3), and it has cosmetic effects such as giving elasticity to the skin. If it exists, it is also used as health food together with collagen etc. (for example, Patent Documents 4 to 6). Furthermore, water soluble elastin is in the field of regenerative medicine such as artificial blood vessels! Even so, its use is expected (for example, Patent Documents 7 to 10).
- Patent Document 1 Japanese Patent Application Laid-Open No. 60-258107
- Patent Document 2 Japanese Patent Application Laid-Open No. 60-181005
- Patent Document 3 Japanese Patent Application Laid-Open No. 2002-205913
- Patent Document 4 Japanese Patent Application Laid-Open No. 6-7092
- Patent document 5 Unexamined-Japanese-Patent No. 2005-13123 gazette
- Patent Document 6 Japanese Patent Application Laid-Open No. 2005-13124
- Patent Document 7 Japanese Examined Patent Publication No. 6-30616
- Patent Document 8 JP-A-8-33661
- Patent Document 9 Japanese Patent Application Laid-Open No. 9-173361
- Patent Document 10 International Publication 2002Z96978 Pamphlet [0004] A variety of methods have been proposed for obtaining water-soluble elastin, but methods for obtaining high-purity water-soluble elastin having a suitable molecular weight are not yet sufficient. Elastin is extracted from biological tissues of animals. In this case, animal biological tissues that have been subjected to pretreatment such as removal of unnecessary parts and defatting are usually used. Then, insoluble elastin contained in animal biological tissue is fragmented by dissolving the pretreated tissue in an acid solution at a predetermined temperature containing formic acid and oxalic acid, or treating with an enzyme. A solubilization solution in which water-soluble elastin is dissolved is obtained.
- Non-patent Document 1 water-soluble a elastin and ⁇ elastin can be obtained by subjecting purified insoluble elastin to extraction treatment with thermal oxalic acid.
- Non-Patent Document 1 the molecular weight of ⁇ -elastin reported in Non-Patent Document 1 is 70, 000, and / 3 the molecular weight of elastin is 10, 000 or less, and the highly pure water-soluble elastin of the present invention described below It is different.
- Patent Document 1 discloses that insoluble elastin is degraded by proteinase to obtain soluble elastin having a molecular weight of 15,000-300,000. However, this elastin has a very broad molecular weight range and is considered to be highly pure, including fragments of enzyme degradation and the like.
- Patent Document 7 also reports that the insoluble elastin is pepsin decomposed to obtain a water-soluble elastin having a molecular weight of 8, 300 to 640, 000.
- the amino acid composition of this product (especially proline, glycine, Judging from lanin and palin), it can not be considered as high in purity.
- Patent Document 10 it is also reported in the above-mentioned Patent Document 10 that insoluble elastin is treated with heat oxalic acid to obtain water-soluble elastin, which is presumed to be of high purity according to the amino acid compositional power. Force In this document, the water soluble elastomer obtained is crosslinked in order to obtain a biocompatible functional material.
- the amino acid composition of the purified insoluble elastin partially overlaps with that of the high-purity water-soluble elastin of the present invention, and 80 to 83% are proline, glycin, haranine and parin, and 2 to 3% Asparaginic acid and glutamic acid;
- Non-Patent Document 2 It has been reported that 0% is lysine, histidine, arginine and 0.3 to 0.4% is a desmosine and isodesmosine potency (eg, Non-Patent Document 2).
- Non-patent literature l Biochimica et Biophysica Acta, 310 (1973) 481-486
- Non Patent Literature 2 nalytical Biochemistry, 64 (1975) 255-259
- the object of the present invention is to provide a low molecular weight and high purity water soluble elastin that can be used as functional food and medicine, and a high molecular weight and high purity, water soluble elastin that can be used as cosmetics and medical materials. It is. Another object of the present invention is to provide a method for industrially producing high purity water-soluble elastin.
- elastin 79 to 84% of the amino acids constituting elastin consist of proline, glycine, analanin and norrin, and 2 to 3% consist of aspartic acid and glutamic acid,
- 3% consisting of lysine, histidine and arginine, and 0.2 to 0.4% also consisting of desmosin and isodesmosinka.
- the content of asparaginic acid also includes asparagine
- the content of Daltamic acid also includes glutamine.
- 79 to 84% of the amino acids constituting elastin are composed of proline, daricin, aranin and norrin, and 2 to 3% is aspartic acid and glutamic acid, 0.7 to 7
- a high molecular weight water soluble elastin having a molecular weight of about 3 to 300,000, of which 1.3% consists of lysine, histidine and arginine, and 0.2% to 0.4% both desmosine and isodesmosine.
- the invention according to claim 3 relates to the method for producing water-soluble elastin according to claims 1 and 2. That is, in the method of producing water-soluble elastin of animal tissue, (1) insoluble elastin is obtained by subjecting animal tissue to collagen removal treatment Step (2) dissolving the insoluble elastin in a solubilizing solution to obtain an elastin dissolving solution; (3) separating the elastin dissolving solution from the upper layer into two layers by a phase separation operation; This method is a process for producing water-soluble elastin, which is also a process step of recovering water-soluble elastin and recovering high molecular weight water-soluble elastin from the lower layer.
- the invention according to claim 8 relates to another method for producing the water-soluble elastin according to claims 1 and 2. That is, in the method of producing water-soluble elastin from animal biological tissue, (1) pretreating the animal biological tissue; (2) immersing the pretreated animal biological tissue in an alkaline solution; Alkaline extraction step of removing the solution containing collagen and other unwanted proteins extracted from the living body tissue, (3) after repeating the procedure of (2) above, it was released by dissolving animal body tissue residue (4) The solution containing the water-soluble elastin recovered in the alkali dissolution step is separated into two layers by phase separation operation, and the low molecular weight water-soluble elastin is separated from the upper layer It is a method for producing water-soluble elastin, which is also a process step of recovering and recovering high molecular weight water-soluble elastin from the lower layer.
- 79 to 84% of the amino acids constituting elastin are also proline, glycine, analanin, and a linker, and 2 to 3% consist of aspartic acid and glutamic acid, 7 to 1.3% consists of lysine, histidine, arginine, 0.24 to 0.4% becomes desmosine and isodesmosinka, functions including low molecular weight water-soluble elastin with a molecular weight of about 1 to 30,000 It is a sex food.
- elastin in the invention according to claim 14, 79 to 84% of the amino acids constituting elastin are composed of purine phosphate, glycine, analanin and norin, and 2 to 3% are composed of aspartic acid and glutamic acid, Low molecular weight water-soluble elastin with a molecular weight of about 1 to 30,000, consisting of 0.3 to 1. 3% consisting of lysine, histidine and arginine and 0.2 to 0.4% also desmosine and isodesmosine It is a medicine as an ingredient.
- the invention according to claim 16 is an arteriosclerosis inhibitor
- the invention according to claim 17 is an agent for improving dyslipidemia
- the invention according to claim 18 is a thrombus formation. It is an inhibitor.
- a low molecular weight, high molecular weight, water soluble elastin having a molecular weight of about 1 to 30,000 and a high molecular weight, high molecular weight, water soluble elastin having a molecular weight of about 3 to 300,000 are provided.
- the low molecular weight water-soluble elastin of the present invention is highly digestible and absorbable, and thus can be used as functional food and medicine.
- high molecular weight water soluble elastin can be used as a cosmetic or medical material.
- insoluble elastin is first produced in a highly pure state by a collagen removal treatment for removing animal body tissue collagen. That is, first, most of the remaining components of the animal tissue of the living body are treated with collagen, which is a contaminant during water-soluble elastin purification, by carrying out a treatment with an emphasis on removing collagen contained in the animal tissue. It can be high purity insoluble elastin.
- the insoluble elastin is fragmented to form a water-soluble elastin, which is liberated and dissolved in the soluble gelatin solution while collagen Since it does not elute, it is possible to produce water-soluble elastin with less impurities and high purity.
- the alkaline extraction step and the alkaline dissolution step of immersing the animal biological tissue in an alkaline solution include collagen removal treatment and collagen treatment.
- the removal process of unnecessary proteins other than the above, fragmentation of insoluble elastin, and soluble / soluble treatment are collectively performed, and water-soluble elastin with high purity can be used to purify insoluble elastin in animal tissues. Processing time can be shortened by collecting
- FIG. 1 is a flow diagram showing a method of producing water-soluble elastin (the invention of claim 3).
- FIG. 2 A flow diagram showing a method of producing water-soluble elastin (the invention of claim 8).
- FIG. 3 A diagram showing changes in total cholesterol in serum.
- FIG. 4 shows changes in LDL-cholesterol.
- FIG. 5 is a diagram showing changes in HDL-cholesterol.
- FIG. 6 shows changes in triglycerides.
- FIG. 7 shows changes in peracid lipid.
- FIG. 8 is a diagram showing changes in the elastic modulus of blood vessels.
- FIG. 9 is a view showing the state of the intimal surface on the blood flow side of a blood vessel.
- FIG. 10 is a view showing the platelet aggregation inhibitory action.
- FIG. 11 is a diagram showing viscosity in blood.
- water-soluble elastin of the present invention 79 to 84% of the amino acids constituting elastin are composed of proline, glycine, analanin and norrin, and 2 to 3% of aspartic acid and glutamate have an activity of 0.7.
- Low molecular weight water-soluble elastin with a molecular weight of about 1 to 30,000, with ⁇ 1.3% consisting of lysine, histidine, arginine, and 0.2 to 0.4% desmosine and isodesmosinka, and molecular weight There are about 30,000,000 high molecular weight water soluble elastin.
- the amino acid composition of the purified insoluble elastin is 80 to 83% strength S proline, glycine, aranin, parin, 2 to 3% is asparaginic acid and glutamic acid, 0.7 to 1.0% is lysine, histidine, Arginine, 0.3 to 0.4% is said to be desmosine and isodesmosine, and the amino acid composition of the water-soluble elastin of the present invention is almost similar to this, so that it is of high purity. I can say that.
- elastin amino acid analysis usually Carohydrolysis with 6N hydrochloric acid for 48 hours or more, so Asn is converted to Asp and Gin is converted to Glu, the value of Asp is the sum of Asp + Asn.
- the value of Glu is expressed as the sum of Glu + Gin.
- the content of asparaginic acid includes the original asparagine, and the content of daltamic acid is defined as including the original glutamine.
- the high purity water-soluble elastin of the present invention can be produced by the following two methods.
- the first method is the method described in claim 3. That is, in the method of producing water-soluble elastin from animal body tissue, (1) a step of obtaining insoluble elastin by subjecting animal body tissue to a collagen removal treatment, (2) dissolving the insoluble elastin into a soluble collagen solution. (3) the elastin solution is separated into two layers by a phase separation operation, and a low molecular weight water-soluble elastin is recovered from the upper layer, and a high molecular weight water soluble elastin is collected from the lower layer. It is a process that recovers
- animal body tissue There is no particular limitation on the animal body tissue, but the content of elastin is high, in terms of pig, It is preferable to use a ligament or aortic vessel obtained from mammals such as horses, cattle and sheep.
- the animal tissue may first be homogenized using a homogenizer. Homogenization is good if it can shred animal tissue such as mixer and meat chopper
- an apparatus that can be shredded into preferably 3 mm square or less, more preferably in the form of a paste.
- the smaller particles of shredded animal biological tissue are preferred because they can increase the removal efficiency of collagen and other unnecessary proteins.
- the homogenized animal tissue may be subjected to a degreasing treatment, for example, by boiling with hot water or a hot dilute aqueous alkali solution, or by treatment with an organic solvent.
- step (1) of the first method it is preferable to remove collagen with an alkaline solution.
- one or more alkali compounds selected from the group consisting of sodium hydroxide, potassium hydroxide, calcium hydroxide and hydroxyl hydroxide are also preferably used in an amount of 0.5 to 0.5 mol per liter of solution, preferably Is preferably 90 to 105 ° C., preferably 95 to 100 ° C., for 10 to 20 minutes, in an alkaline solution containing 0.5 to 0.5 mol, more preferably 0.5 to 0.5 mol.
- a treatment method in which immersion is performed is preferred (Claim 4).
- the insoluble elastin is fragmented and released by the alkaline solution as well as the acidic solution, and the force to become the soluble aqueous elastin that can be dissolved is the concentration of the alkaline solution, the temperature, and the treatment time in the above collagen removal treatment operation.
- the conditions are conditions in which collagen elutes earlier than insoluble elastin fragments into water soluble elastin and releases and dissolves. Therefore, by the treatment under the above conditions, collagen in animal tissues can be efficiently eluted and removed in an alkaline solution, and as a result, highly pure insoluble elastin can be obtained.
- the alkaline solution in the collagen removal treatment has an effect of removing unnecessary proteins other than collagen as well as extracting and removing collagen.
- the collagen removal treatment may be repeated several times until the concentration of the protein eluted in the filtrate obtained by filtering out the alkaline solution and insoluble elastin becomes equal to or less than a predetermined value. If the treatment is under the above conditions, the collagen removal treatment is repeated until the concentration of eluted protein (ie the concentration of eluted collagen etc.) reaches a predetermined concentration. Also, fragmentation against insoluble elastin is less likely to occur. Therefore, by repeatedly removing collagen, it is possible to produce water-soluble elastin having a higher degree of purification than when collagen removal is performed only once.
- one or more salts selected from sodium chloride, potassium chloride, calcium chloride and barium chloride are selected before the collagen removal treatment. Dip the animal tissue at 2 to 10 ° C. for 12 to 48 hours, preferably 20 to 30 hours, in a salt solution containing 0.1 to 2 mol, preferably 0.8 to 1.2 mol, per liter of solution Immersion treatment may be performed (claim 5). Unwanted proteins other than collagen can be removed in advance by this treatment, which may be carried out several times by treatment with a strong salt solution.
- an alkaline solution may be used.
- the acidic solution include oxalic acid, formic acid, acetic acid, succinic acid, malic acid, tartaric acid, tartaric acid, benzoic acid, betaine, difluoroacetic acid, trifluoroacetic acid, phosphoric acid, sulfamic acid and perchloric acid. And 0.1 to 0.5 mol, preferably 0.2 to 0.3 mol, per liter of the solution, and the liquid temperature is 90 to 105, and the acid compound is selected from the group consisting of It is an acidic solution at a temperature of 95 ° C to 100 ° C (Claim 6).
- Such conditions are suitable conditions for producing insoluble elastin and water soluble elastin, but are also suitable conditions that do not shred the water soluble elastin molecule that has been free dissolved in the solubilization solution.
- Water soluble elastin with sufficient molecular weight can be produced.
- the treatment time for the solubilization is 20 to 120 minutes, preferably 40 to 80 minutes. If insoluble elastin remains, re-immerse the insoluble elastin in the acid solution and repeat the treatment with the acid solution until the insoluble elastin is completely dissolved.
- the alkaline solution include sodium hydroxide, potassium hydroxide, calcium hydroxide, and one or more alkali compounds selected from the group consisting of barium hydroxide, per 1 L of solution. It is an alkaline solution containing 0.5 to 0.5 mol, preferably 0.5 to 0. 3 mol, and having a liquid temperature of 90 to 105 ° C, preferably 95 to 100 ° C (claim 7). Such conditions are suitable for producing insoluble elastin, water soluble elastin, while soluble. It is also an appropriate condition that the water soluble elastin molecule dissolved free 'dissolved in the formulation solution is not shredded, so that water soluble elastin having sufficient molecular weight can be produced.
- the treatment time for the solubilization is 20 to 120 minutes, preferably 40 to 80 minutes. If insoluble elastin remains, re-immerse the insoluble elastin in the alkaline solution and repeat the treatment with the alkaline solution until the insoluble elastin is completely dissolved.
- the alkaline solution used in the collagen removal treatment can be used subsequently as the soluble solution, and in this case, the manufacturing cost can be reduced.
- the separated upper layer The low molecular weight water-soluble elastin is recovered from the water, and the high molecular weight water-soluble elastin is recovered from the separated lower layer.
- the properties of the obtained water-soluble elastin will be described in detail later.
- FIG. 1 A flow diagram for producing water-soluble elastin by the first method is shown in FIG.
- FIG. 1 The processing conditions and the like in FIG. 1 are an example of the present invention.
- Step S1 Using the ligamentum flavum of the animal as the animal body tissue, attach the attached / excluded fat, muscle and other parts with low elastin content with a knife etc (Step S1), remove the animal body tissue. Homogenize using a homogenizer (step S2). For homogenization, it is preferable to use an apparatus such as a mixer or mit chopper that can shred animal tissue preferably 3 mm square or less, more preferably paste. The smaller particles of shredded animal tissue can increase the removal efficiency of unnecessary proteins.
- Homogenized animal biological tissue is used in boiling water (90 ° C-105 ° C, preferably 2 volumes or more, preferably 2-20 volumes of animal tissue weight or more, preferably 2-20 volumes).
- the term “water drainage” as used herein is meant to cut off the liquid attached to animal tissues which is not intended specifically for water. If the degreasing time is less than 30 minutes, the degreasing can not be performed sufficiently. Degreasing effect can not be expected.
- a degreasing operation may also be performed using an organic solvent generally used for lipid extraction such as acetone, ethers, hexane, butanol, chloroform, methanol, etc. or a mixture thereof. good.
- drainage may be performed with a fine mesh of eyes, or may be provided with a mesh, or drainage may be performed by centrifugal force. Further, the dehydrated animal tissue is immersed in acetone, ethanol or the like and recovered, and the acetone or ethanol which has permeated the animal tissue is evaporated, whereby the water content of the animal tissue can be dehydrated. Further degreasing can also be performed.
- the drained animal biological tissue is put in a container, and the volume of the saline solution (0.1 to 2 M, preferably D.
- Immersion treatment is carried out by stirring 8 to 1.2 M aqueous sodium chloride solution and stirring at 2 to 10 ° C. for 12 to 48 hours, preferably 20 to 30 hours (step S5).
- unnecessary proteins other than collagen can be removed in advance.
- the immersion treatment may freeze below 2 ° C, and when it exceeds 10 ° C, microbial growth can be observed. In one immersion treatment time, extraction of unnecessary proteins is insufficient in 12 hours or less, and it is unnecessary to exceed 48 hours.
- a sodium chloride aqueous solution is used as the salt solution used in the immersion treatment in FIG. 1, at least one of sodium chloride, potassium chloride, calcium chloride and barium chloride is used.
- the total amount of sodium chloride, potassium chloride, calcium chloride and barium chloride added to the salt solution is 0.1 to 2 mol per liter, preferably 0.8 to 1. It is desirable to use a salt solution at 2-10 ° C at 2mo 1! /. For example, after immersion treatment of 10 volumes of 1 M aqueous sodium chloride solution at 4 ° C. for 24 hours with respect to animal tissue weight, animal tissue and salt solution are separated, For the separated salt solution, the total protein is quantified, for example, by the burette method (step S6).
- the immersion treatment is performed again, in the salt solution. If the total protein weight contained in is 0. Img / mL or less, it is judged that unnecessary proteins have been removed and the operation is transferred to the next step S7.
- the intensive immersion treatment may or may not be performed, but may be performed multiple times, but generally, as the number of times is increased, unnecessary proteins can be removed, and the insoluble elastin content is high. And animal-derived living tissue can be obtained.
- an alkaline solution (0.5 to 0.5 M, preferably 0.2 parts by volume or more, preferably 2 to 20 times the volume of the weight of the animal body tissue subjected to the immersion treatment relative to the weight of the tissue) is used.
- 05-0. 3M in a further preferred 0.
- 05-0. 15M Mizusani ⁇ Na Bok helium aqueous solution to a human being, 90 to 105 o C, preferably rather 10-20 minutes at 95 to 100 ° C Stir and perform collagen removal treatment (step S7).
- the amount of the alkaline solution is less than twice the volume of the weight of the living animal tissue, the extraction efficiency of collagen becomes worse, and if it is more than 20 volumes, it is difficult to handle, so 2 to 20 times the weight of the living animal tissue. It is desirable to perform collagen removal treatment by volume.
- the collagen removal treatment time is less than 10 minutes, the removal efficiency of collagen is poor, and when it is more than 20 minutes, elastin is degraded.
- the alkaline solution in FIG. 1, at least one of sodium hydroxide, potassium hydroxide, calcium hydroxide and barium hydroxide, which uses a sodium hydroxide aqueous solution, is used.
- the total amount of sodium hydroxide, potassium hydroxide, calcium hydroxide and barium hydroxide added to the alkaline solution is 0.05 to 0.5 mol per liter, preferably 0. It is also possible to use an anololytic solution of 0.5 to 0.3 mol, more preferably 0.5 to 0.5 mol.
- step S8 After removing collagen by 10 volumes of 0.1 M aqueous solution of sodium hydroxide at 100 ° C. for 15 minutes with respect to the weight of animal tissue, the animal tissue and alkali The alkaline solution separated from the alkaline solution is separated, for example, by the burette method. The determination of the particulate matter is performed (step S8).
- the total amount of protein contained in the alkaline solution exceeds, for example, 0.1 mg / mL, collagen removal treatment is performed again, judging that collagen capable of further removal exists in the animal body tissue, If the total amount of protein contained in the alkaline solution is 0.1 mg / mL or less, it is judged that the collagen has been removed and the collagen removal treatment is terminated to obtain insoluble elastin of high purity.
- the insoluble elastin is covered with a two-fold volume, preferably a two- to twenty-fold volume, of the solubilization solution by weight, preferably 90 to 105 ° C., preferably 95 to 100 ° C.
- the insoluble elastin is fragmented by stirring for ⁇ 120 minutes, preferably for 40-80 minutes, and it is dissolved in a soluble emulsion as a water-soluble elastin (step S9).
- the soluble concentrate used here may be any other acidic solution which uses oxalic acid in FIG. 1 or it may be an alkaline solution.
- the acidic solution examples include, for example, oxalic acid, formic acid, acetic acid, succinic acid, malic acid, tartaric acid, tartaric acid, benzoic acid, betaine, difluoroacetic acid, trifluoroacetic acid, phosphoric acid, sulfamic acid and perchloric acid. And an acid solution containing at least one of acetic acid having a total amount of these acids of 0.1 to 0.5 mol, preferably 0.2 to 0.3 mol, per liter. Saru.
- the alkaline solution is, for example, an alkaline solution containing at least one of sodium hydroxide, potassium hydroxide, calcium hydroxide and barium hydroxide, which may be contained in the alkaline solution.
- the total amount of sodium hydroxide added, potassium hydroxide, calcium hydroxide and hydroxylated hydroxide was adjusted to 0.5 to 0.5 mol, preferably 0.5 to 0.5 mol, per liter.
- An alkaline solution can be used.
- Step S10 After immersing in a soluble solution containing 10 volumes of a 0.25 M aqueous oxalic acid solution at 100 ° C. for 60 minutes relative to the weight of animal tissue, for example, insoluble elastin and soluble aqueous solution can be used.
- the filtrate is separated (Step S10), and the separated soluble liquid is allowed to stand at 25 ° C. or less by cooling or water cooling or the like, preferably at 10 ° C. or less by ice cooling or the like (Step Sl 1). That is, by setting the separated solubilization solution at 25 ° C. or less, preferably at 10 ° C.
- Step S 13 the pH of the solubilized solution in which the water-soluble elastin is dissolved is adjusted to 5 to 7, preferably 6 to 7, and the solubilized solution is dialyzed.
- a soluble solution freed and dissolved in water-soluble elastin is placed in a bag formed of a semipermeable membrane and sealed, and then dialyzed against water at 4 to 10 ° C. While elastin is retained in the bag, the components contained in the soluble solution are eluted outside the semipermeable membrane to purify water-soluble elastin.
- a method in performing dialysis is not limited to the method using a semipermeable membrane, with water-soluble elastin molecules recoverable state, capable of removing salt form raw upon the other ingredients and P H adjustment during lysates If it is, what kind of method may be used. After 24 hours, it is preferable to discard the water used for dialysis, dialyze again with fresh water at 4 to 10 ° C. for 24 hours, and repeat this four times or more.
- the dialyzed water-soluble elastin undergoes phase separation by setting the temperature of the aqueous solution to 30 to 50 ° C. (step S 14), and the upper layer (equilibrium liquid phase) containing low molecular weight aqueous solution elastin and high water content are obtained. It separates into the lower layer (coacervate phase) containing molecular weight water-soluble elastin (step S15).
- the tissue culture is often performed at about 37 ° C. Therefore, coacervation occurs at 37 ° C. or lower. It is desirable to efficiently recover high molecular weight water soluble elastin.
- phase separation can be performed if elastin is in a water-soluble state, but preferably after adjusting the pH after dialysis to pH 3 to pH 7, more preferably, the pH is near the isoelectric point of water-soluble elastin After adjustment to pH 4 to pH 6, high molecular weight water soluble elastomer can be efficiently obtained.
- the high molecular weight water-soluble elastin of the present invention is recovered from the above-described coreserate phase, and the low molecular weight water-soluble elastin of the present invention is circulated from the upper layer (equilibrated liquid phase) separated therefrom. Be collected.
- a second method for producing the high purity water-soluble elastin of the present invention is the method described in claim 8. That is, in the method for producing water-soluble elastin of animal tissue, (1) pretreating the animal tissue, (2) immersing the pretreated animal tissue in an alkaline solution. And an alkaline extraction step of removing a solution containing collagen and other unwanted proteins extracted by the animal body tissue, and (3) animal body tissue residue after repeating the operation of (2).
- the solution containing the water-soluble elastin separated in the alkaline dissolution step of recovering the solution containing the released water-soluble elastin is dissolved into two layers by the phase separation operation.
- the method is a process for producing water-soluble elastin, comprising the step of recovering low molecular weight water-soluble elastin from the upper layer and recovering high molecular weight water-soluble elastin from the lower layer.
- Step 2 of the Second Method (2) In the alkaline extraction step, the pretreated animal tissue is divided into sodium hydroxide, potassium hydroxide, calcium hydroxide and barium hydroxide.
- Anololytic activity containing 0.5 to 0.5 mol, preferably 0.5 to 0.5 mol, more preferably 0.5 to 0.15 mol per 1 L of solution. It is preferred to immerse in the solution at 90 to 105 ° C., preferably 95 to 100 ° C., for 10 to 20 minutes (claim 9). Then, the solution extracted by the animal tissue is removed. Such treatment removes collagen and other unwanted proteins.
- the residual animal tissue residue is dissolved, and the solution is recovered.
- the remaining animal biological tissue residue is treated with one or more than one selected from the group consisting of sodium hydroxide, potassium hydroxide, calcium hydroxide and barium hydroxide.
- Elution of collagen and other unwanted proteins with alkaline solution under the above conditions is carried out prior to fragmentation of insoluble elastin. Therefore, in the alkaline extraction step of (2) of the second method, The amount of elution of unnecessary proteins including collagen decreases each time the extraction of sexual tissue strength is repeated, and the concentration of proteins such as collagen becomes an exponentially gradually diluted solution. Next, in the alkaline dissolution step (3), the remaining animal tissue residue is dissolved, whereby the water-soluble elastin is liberated and dissolved in the alkaline solution. In the methods (2) and (3), by changing the concentration of the alkaline solution and the treatment time, the ability to remove unnecessary proteins including collagen is also interrupted intermittently until recovery of the water-soluble elastin. Since it can be a series of operations, water-soluble elastin can be produced in a short time.
- step (4) of the second method the solution containing elastin recovered in the alkali dissolution step (3) is phase-separated, and from the separated upper layer, low molecular weight water-soluble elastin Is recovered. Also, high molecular weight water-soluble elastin is recovered from the separated lower layer.
- Such recovery step can be performed in the same manner as in the first method.
- FIG. 1 A flow diagram for producing water-soluble elastin by the second method is shown in FIG.
- water-soluble elastin can be produced in a short time from animal tissue.
- the processing conditions and the like in FIG. 2 are an example of the present invention.
- the animal tissue is attached to the calf's ligament and attached! / A portion with low elastin content such as fat and muscle meat scraped off with a knife etc. Removal treatment (step T1), and shredding treatment is carried out by homogenizing the animal body tissue using a homogenizer as in the first method (step T2). Such pretreatment step can be carried out in the same manner as in the first method.
- the animal body tissue is contained in a volume 2 times or more, preferably 2 to 20 times, the volume of the tissue, preferably 2 to 20 volumes of an alcoholic acid solution (0.50 to 0.5M, preferably 0. 05 0.30, more preferably 0. 05 to 0.
- step T3 15 M aqueous solution of sodium hydroxide), 90 to 105 ° C., preferably 95 to: LO: 10 to 20 minutes of stirring at 0 ° C. and alkali Perform the extraction process (step T3). Thereafter, the animal tissue residue and the alkaline solution are separated, and the separated alkaline solution is subjected to quantification of total protein, for example, by the billet method (step 4). If the total amount of protein contained in the alkaline solution is, for example, more than 0. I mg / mL, it is judged that collagen and other unwanted proteins can be further removed from the animal body tissue, so that collagen etc. is removed The treatment is repeated, and if the total amount of protein contained in the alkaline solution is 0.1 mg / mL or less, it is judged that collagen and other unnecessary proteins have been removed, and the removal process of collagen etc. is finished.
- the amount of the alkaline solution is less than twice the volume of the weight of the living animal tissue, the extraction efficiency of collagen and unnecessary proteins is deteriorated, and when it exceeds 20 times the volume, it is difficult to handle.
- a volume of 2 to 20 times the tissue weight is desirable.
- the immersion time is less than 10 minutes, the removal efficiency of collagen and other unwanted proteins is poor, and when it exceeds 20 minutes, elastin is degraded and extracted, so it is desirable to perform for 10 to 20 minutes.
- alkaline solution another alkaline solution having a sodium hydroxide aqueous solution may be used as shown in FIG.
- one or more of sodium hydroxide, potassium hydroxide, calcium hydroxide and barium hydroxide in a total amount of 0.05 to 0.5 mol, preferably 0.5 to 0.5 mol, per liter It is desirable to use an alkaline solution which is preferably adjusted to 0.05 to 0.15 mol.
- the alkali extraction step also has the effect of degreasing animal tissue. Therefore, although the degreasing treatment in the pretreatment step is omitted in FIG. 2, unnecessary lipids may be further removed by performing the degreasing operation as shown in FIG.
- an animal biological tissue residue subjected to the alkali extraction step is at least 2 volumes, preferably 2 to 20 volumes of an alkaline solution (0.05 to 0.5 M, preferably D. 0.50 to 0.3 D soak in 3 M aqueous solution of sodium hydroxide), 90 to 105 ° C., preferably 95 to: LOO.
- Water-soluble elastin is released by dissolving animal tissue residue by stirring at C for 20 to 240 minutes, preferably 40 to 120 minutes (step T5).
- Alkaline solution In FIG. 2, other alkaline solutions may be used, in which the aqueous solution of sodium hydroxide is used.
- one or more of sodium hydroxide, potassium hydroxide, calcium hydroxide and barium hydroxide the total amount of which is 0.05 mol per liter of solution, preferably 0.0 mol. It is desirable to use an alkaline solution U ,. If residual animal tissue remains, separate the remaining aqueous alkaline tissue solution from the alkaline solution containing the water-soluble elastin and the remaining undifferentiated animal tissue residue (step T6). Re-apply to the dissolution process (Step T7)
- the temperature is allowed to stand by cooling, cooling to 25 ° C. or less, preferably 10 ° by ice cooling, etc. Lower it to C or lower (step T8), adjust to a pH near neutrality (step T9), and perform crystallization (step T10).
- Means of dialysis ⁇ The method can be performed in the same manner as the first method.
- the dialyzed adjusting solution performs phase separation by setting the temperature of the aqueous solution to 30.degree. C. (step T11), and the low molecular weight aqueous solution elastin is used. It is separated into the upper layer (equilibrated liquid phase) containing and the lower layer (coacerv phase) containing high molecular weight water-soluble elastin (step T12).
- the step of recovering the low molecular weight aqueous solution elastin and the high molecular weight water soluble elastin can be carried out in the same manner as in the first method.
- the protein content in the alkaline solution after collagen removal treatment is measured for each collagen removal treatment using a protein quantification method such as the burette method, the end point of the procedure. Can be determined.
- a protein quantification method such as the burette method
- a spectrophotometer for example, at a wavelength around 540 It may be taken as an end point when the concentration becomes lower than a predetermined value.
- the treatment is performed to such an extent that the reddish purple can not be confirmed with the naked eye, it may be used as the end point of the immersion treatment.
- the predetermined value can be determined by the desired purity of the water-soluble elastin. For example, when a 10-fold volume of an alkaline solution is added to the weight of a living animal tissue, a predetermined value in the case of obtaining water-soluble elastin of relatively high purity is, for example, 0
- the predetermined value in the case of obtaining water soluble elastin of higher purity with lmg / mL can be, for example, 0.1 lmg / mL or less.
- the term “end when the value is less than or equal to the predetermined value” includes the force at the time when the value is less than or equal to the predetermined value and the process is repeated to end the process.
- the solubilization of insoluble elastin is repeated intermittently until insoluble elastin dissolves and disappears, so that the soluble gelatinous solution can be dissolved. It is possible to prevent shreds of water-soluble elastin dissolved in it. That is, after 20 to 120 minutes, preferably 40 to 80 minutes of immersion in the solubilizing solution, the soluble syrup is discontinued and the soluble syrup obtained by separating it from the insoluble elastin is continuously treated.
- the water-soluble elastin dissolved in the solubilizing solution is separated into two layers by performing a phase separation operation, whereby the low molecular weight water-soluble elastin fraction of the upper layer (equilibrated liquid phase) and the lower layer Phase can be fractionated into high molecular weight water soluble elastin fractions. Since only a high molecular weight water-soluble elastin forms a coacervate phase by hydrophobic association between molecules and forms a coacervate phase, a high molecular weight water-soluble elastin can be efficiently obtained by obtaining a coacervate phase. It can be recovered.
- the pH of the water-soluble elastin to 3 to 7, preferably pH 4 to 6, at the time of phase separation, it becomes near the isoelectric point of elastin, so that it becomes easier to form a core cell bed phase, Recovery of high molecular weight water soluble elastin can be increased.
- insoluble elastin since insoluble elastin is actually removed from the reaction system, it is advantageous to be able to analyze the amino acid composition and the like of the removed insoluble elastin and to verify its purity.
- insoluble elastin is stable and can be stored for a long time, and there is an advantage that the solubilization method can be selected by either acid treatment or alkali treatment.
- the second method since insoluble elastin is not removed, the process is simple, and only by adjusting the concentration of the alkaline solution and the reaction time, highly pure water-soluble elastin can be obtained. Therefore, the latter is characterized in that water-soluble elastin can be obtained with a high yield.
- the water-soluble elastin obtained by the first or second method has a low molecular weight (about 13 to about 10,000 molecular weight) water-soluble elastin and a high molecular weight (about a molecular weight of about 30 to 30,000) by phase separation. 3 to 300,000) Perform an operation to fractionate into water-soluble elastin. That is, when water-soluble elastin is heated to 30 ° C. to 50 ° C., it phase separates and becomes cloudy, and when left as it is, it separates into two layers.
- the coacervation characteristics of low molecular weight water-soluble elastin and high molecular weight water-soluble elastin that is, the increase in turbidity with increasing temperature and the reversible property of returning turbidity with decreasing temperature
- high molecular weight water-soluble elastin becomes cloudy when heated, and since the turbidity curve is reversible, it is expected that high molecular weight water-soluble elastin can be applied to cosmetics and medical materials.
- low molecular weight water-soluble elastin is difficult to use in cosmetics and medical materials because it does not become cloudy upon heating. While low molecular weight water-soluble elastin is small in molecular weight size, it is considered to be suitable for food materials and medicines because it is advantageous in terms of digestion and absorption.
- the collagen solution becomes cloudy when heated. It remains cloudy even if the temperature is lowered, and it does not return to its original clear state (irreversible).
- the solution of water-soluble elastin becomes cloudy when heated and returns to the original transparent state (reversibility) when the temperature is lowered.
- collagen is denatured when the heating temperature is extremely raised and it changes to gelatin which is different in nature from collagen, but there is also a difference that elastin remains elastin even if the heating temperature is extremely raised.
- collagen and elastin can be applied to appropriate medical materials. It can also be used to verify the presence or absence of collagen contamination depending on whether the turbidity curve of the produced water-soluble elastin is reversible.
- water-soluble elastin of the present invention 79 to 84% of the amino acids constituting elastin consist of proline, glycine, alanine and norrin, and 2 to 3% consist of aspartic acid and glutamic acid, 0.7.
- To 1.3% consists of lysine, histidine, arginine, 0.2 to 0.4%
- a low molecular weight water-soluble elastin having a molecular weight of about 1 to 30,000, which is also a smosin and isodesmosinka, can be used as a functional food because it is excellent in digestion and absorption.
- Elastin about 30%
- collagen about 18%) are the main components that make up blood vessels, although collagen has been widely used as a food material with a skin-refining effect, however, arteriosclerosis using elastin as a material Preventive 'Retardant functional food is still being developed.
- the water-soluble elastin used in this report only differs in amino acid composition from the water-soluble elastin which has been evaluated to be highly pure so far (only 68% of proline, glycine, analanin and norin) Since desmosine and isodesmosine, which are amino acids unique to elastin, are not detected either, it is presumed that they are extremely low in purity or different from elastin! /.
- the low molecular weight water-soluble elastin of the present invention suppresses the elevation of cholesterol, which is described later, the elevation of neutral fat, the elevation of LDL-cholesterol (bad cholesterol), and the decline of HDL-cholesterol (good cholesterol)
- it has an action to improve blood lipid metabolism disorders such as suppression of rise in lipid peroxide, and hardening lesions on the surface of the lumen of blood vessels, and depression of vascular elastic function. It can be expected to be developed as an all-round functional food.
- the low molecular weight water-soluble elastin of the present invention suppresses the increase of cholesterol, suppresses the increase of neutral fat, suppresses the increase of LDL-cholesterol (bad cholesterol), HDL-cholesterol (good cholesterol), which will be described later.
- blood lipid metabolism such as suppression of blood loss reduction, rise of lipid peroxide, suppression of rise of oxidized LDL, action of suppressing thrombus formation, and action of suppressing hardening lesion (hardened plaque) on the lumen surface Of elastic function It has a physiological action such as a drop suppressing action.
- the low molecular weight water-soluble elastin of the present invention is also developed as various therapeutic or preventive medicines containing it as an active ingredient, for example, medicines such as arteriosclerosis inhibitor, lipid metabolism disorder improving agent, thrombus formation inhibitor and the like. Can be expected.
- the low molecular weight water-soluble elastin of the present invention is used as a food or medicament
- metals useful for living bodies that contain it as an active ingredient such as magnesium, calcium, chromium, manganese, iron Alkali earth metals and transition metals such as conort, nickel, copper, aluminum and zinc may be used in combination. Depending on the metal used, a synergistic effect can be obtained.
- the functional food is not particularly limited in its form, but low molecular weight water-soluble elastin having a molecular weight of about 1 to 30,000 as it is prepared as a food and drink as it is, various proteins, saccharides, fats
- the composition may further contain a trace element, vitamins, etc., may be in the form of liquid, semi-liquid or solid, or may be added to general food and drink.
- food is used in a sense that it widely includes health food, health supplements, food for specified health use, etc.
- the functional food of the present invention can be expected to improve blood lipid metabolism abnormality, to suppress the hardening of the surface of the lumen of the blood vessel, and to suppress the reduction of the blood vessel elastic function, It can be provided as a food.
- the medicament can be produced by mixing a low molecular weight water-soluble elastin having a molecular weight of about 1 to 30,000, which is an active ingredient, with a pharmaceutically acceptable additive.
- the medicine of the present invention can be administered orally or parenterally.
- Oral agents include granules, powders, tablets, pills, capsules, syrups, emulsions, suspensions.
- Parenterals include injections and drops. These preparations can be formulated with a pharmaceutically acceptable carrier by means commonly used in the pharmaceutical field.
- the intake of the functional food of the present invention is suitably 30 to 6, OOOmg, preferably 60 to 3, OOOmg in terms of elastin per adult per day.
- OOOmg OOOmg in terms of elastin per adult per day.
- the active ingredient of the present invention is orally administered as a medicine.
- 0.5 to 100 mg / kg body weight preferably 1 to 50 mg / kg body weight, per adult.
- the degreasing step may be performed a plurality of times, and a dilute alkaline solution treatment or an organic solvent treatment may be performed.
- the soaking animal tissue was placed in a 10-fold volume of a 0.1 M aqueous solution of sodium hydroxide and stirred at 100 ° C. for 15 minutes to carry out a collagen removal treatment. Then, the animal tissue and the alkaline solution were separated to obtain pure insoluble elastin. For example, the total protein is quantified by the biuret method, and if the total amount of proteins contained in the alkaline solution is 0.1 mg / mL or less, collagen is removed. I judged. If collagen has not been removed, this operation may be performed several times.
- the recovery rate of low molecular weight water-soluble elastin can be increased by setting the temperature of the aqueous solution to 30 to 40 ° C. When the temperature of the aqueous solution is set to 40 to 50 ° C., the recovery rate of high molecular weight water-soluble elastin Can improve
- the recovery rate of high molecular weight water-soluble elastin can be increased by adjusting pH to pH 7 to pH 7, preferably pH 4 to pH 6, which is near the isoelectric point of water-soluble elastin.
- the yield of low molecular weight water-soluble elastin is 2 to 4%, and the yield of high molecular weight water-soluble elastin is 1 to 2%, based on the calf ligament.
- the upper layer fraction and the lower layer fraction after phase separation are subjected to SDS (sodium dodecyl sulfate) -PAGE (polyacrylamide gel electrophoresis) under non-reducing conditions, and the gel after electrophoresis is stained to obtain the stained band From the above, it was confirmed that the upper layer fraction is a low molecular weight water-soluble elastin having a molecular weight of about 1 to 30,000, and the lower layer fraction is a high molecular weight water-soluble elastin having a molecular weight of about 3 to 300,000.
- SDS sodium dodecyl sulfate
- PAGE polyacrylamide gel electrophoresis
- the amino acid compositions of the low molecular weight water-soluble elastin and the high molecular weight water-soluble elastin were as shown in Table 1.
- the amino acid composition in Table 1 shows the amino acid composition when the total number of amino acids is 1,000.
- Low molecular weight indicates low molecular weight water-soluble elastin having a molecular weight of about 1 to 30,000
- high molecular weight indicates high molecular weight water-soluble elastin having a molecular weight of about 3 to 300,000.
- the content of histidine is about 0.5 to 0.5 per 1,000 amino acid residues. In Table 1, it is 0 by rounding off.
- the animal body tissue uses the calf's ligamentum navy, and scraped off parts with low elastin content, such as attached fat and muscle meat, using a knife etc. to remove unnecessary parts, Then, the animal body tissue was shredded by homogenization using a homogenizer. Homogenized animal tissues were boiled for 1 hour in boiling water for defatting and then drained. If the degreasing is insufficient, the degreasing step may be carried out a plurality of times, or a dilute alkaline solution treatment or an organic solvent treatment may be carried out to improve the degreasing efficiency. If fat is also removed along with the removal of collagen and unwanted proteins in the next alkaline extraction step, the degreasing treatment here is omitted.
- a volume of 10 times the weight (weight lg) of the weight of the homogenized and defatted animal tissue A 0.1M aqueous solution of sodium hydroxide (0.1 mL) was added to the solution and stirred at 100 ° C. for 15 minutes to extract and remove collagen and unwanted proteins other than elastin (alkali extraction step). . Then, the animal tissue residue and the alkaline solution were separated. The separated alkaline solution is used to quantify the total protein by, for example, the biuret method, and if the total amount of protein contained in the alkaline solution is 0.1 mg / mL or less, collagen and unwanted protein are eliminated. I judged that it was removed. Collagen and unwanted proteins are removed! / If this is the case, do this multiple times.
- a 1 M aqueous solution of sodium hydroxide (solubilizing solution) was added, and an alkali dissolution step was performed at 100 ° C. for 60 minutes. Thereafter, the separation operation between the animal tissue residue and the alkaline solution was performed, and the alkaline solution containing the separated water-soluble elastin was cooled to 25 ° C. or less. At this time, in the case where the dynamic biological tissue remains, this alkali dissolution step may be performed multiple times.
- the recovery rate of the low molecular weight water-soluble elastin can be increased, and if the temperature of the aqueous solution is set to 40 to 50 ° C., the high molecular weight water-soluble elastin is recovered. Rates can be increased.
- the recovery rate of high molecular weight water-soluble elastin can be increased by adjusting to pH 3 to pH 7, preferably pH 4 to pH 6, which is near the isoelectric point of water-soluble elastin. By the operation of intensive phase separation, 50 to 70% of the low molecular weight fraction and 20 to 30% of the high molecular weight fraction can be recovered based on the water-soluble elastin.
- the yield of low molecular weight water-soluble elastin is 4 to 12%, and the yield of high molecular weight water-soluble elastin is 2 to 5%, based on the calf ligament.
- the obtained water-soluble elastin is used as a tissue culture substrate for regenerative medicine When used as a tissue culture, since tissue culture is often performed at about 37 ° C., it is desirable to efficiently recover high molecular weight water-soluble elastin that causes coacervation at 37 ° C. or less.
- the upper layer fraction and the lower layer fraction after phase separation are subjected to SDS (sodium dodecyl sulfate) -PAGE (polyacrylamide gel electrophoresis) under non-reducing conditions, and the gel after electrophoresis is stained to obtain the stained band From the above, it was confirmed that the upper layer fraction is a low molecular weight water-soluble elastin having a molecular weight of about 1 to 30,000, and the lower layer fraction is a high molecular weight water-soluble elastin having a molecular weight of about 3 to 300,000.
- SDS sodium dodecyl sulfate
- PAGE polyacrylamide gel electrophoresis
- the amino acid compositions of the low molecular weight water-soluble elastin and the high molecular weight water-soluble elastin were as shown in Table 2.
- the amino acid composition in Table 2 shows the amino acid composition when the total number of amino acids is 1,000.
- Low molecular weight indicates low molecular weight water-soluble elastin having a molecular weight of about 1 to 30,000
- high molecular weight indicates high molecular weight water-soluble elastin having a molecular weight of about 3 to 300,000.
- the content of histidine is about 0.5 to 0.5 per 1,000 amino acid residues.
- rounding off is 0 in Table 2.
- a water-soluble elastin was produced according to the method described in the preparation example of JP-A-60-258107. That is, the calf ligament was treated with sodium chloride, treated with tricloric acid, and then treated with hot water at 120 ° C. to obtain purified elastin. A lactic acid solution was added thereto, the solution was autoclaved, cooled, and then decomposed with the protein degrading enzyme pepsin to produce a water-soluble elastin having an average molecular weight of about 50,000.
- the amino acid composition of the obtained water-soluble elastin was 77% in total of proline, glycine, analanin, and parin, 3.4% in total of aspartic acid and glutamic acid, and a total of 1. It was 5%, and both were different from the composition of the water-soluble elastin of the present invention.
- the water-soluble elastin of the comparative example is presumed to be contaminated with collagen, in contrast to the fact that hydroxyproline was 15% and 7% of the example 1 or 2 of the present invention was 7%.
- the turbidity start temperature was about 10 ° C. higher than that of Example 1 or 2. It was This seems to indicate that the comparative example is low in molecular weight and low in purity and purity. In addition, the yield as water-soluble elastin of Example 2 was 11% based on the defatted tissue, while that of the comparative example was only 3%.
- the low molecular weight water-soluble elastin of the present invention has an effect of improving blood lipid metabolism disorders.
- it is understood that it has potential as a functional food material having an arteriosclerosis inhibitory action, and as a medicine having an improvement in blood lipid metabolism abnormality and, in turn, an arteriosclerosis inhibiting action.
- the average modulus of elasticity in the range was determined and used as Elastic Modulus in the control group receiving a normal diet, cholesterol group receiving a cholesterol diet, and cholesterol plus elastin combination group receiving a water-soluble elastin simultaneously with a cholesterol diet. It compared and examined. The results are as shown in FIG. 8. It can be seen that the administration of water-soluble elastin restored the decrease in the elastic function of the blood vessel.
- FIG. 9 shows a photograph of the intimal surface on the blood flow side of the blood vessel.
- atheromatous plaques thickening of the intima of the endothelium and deposition of lipids (cholesterol and the like) produce a scaly substance, and a raised state in which the intimal surface is covered with a fibrous coating.
- the blood flow is impeded by increasing the size of the large protuberance, and in very thin blood vessels such as coronary arteries, occlusion of the blood vessels is observed, causing myocardial infarction). Appear white).
- the concentration of lipids such as cholesterol in the blood increases, or platelets Then, the viscosity of the blood (blood viscosity) was measured because the blood viscosity was increased and dripping was observed. The results are shown in FIG. It can be seen that the blood viscosity rising with the administration of cholesterol is improved by the administration of water-soluble elastin.
- a low molecular weight and high purity water soluble elastin and a high molecular weight and high purity water soluble elastin can be obtained.
- the low molecular weight water-soluble elastin of the present invention is highly digestible and absorbable, it can be used as functional food and various medicines.
- high molecular weight elastin is applied to scaffolds for tissue engineering for regenerative medicine, and since high molecular weight water-soluble elastin coacervate contains 60 to 70% water, it is suitable for moisturizing properties.
- Application to a cosmetic base is conceivable.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006543232A JP4078431B2 (ja) | 2004-10-29 | 2005-10-27 | 水溶性エラスチンとその製造方法及びそれを含む食品と医薬 |
US11/666,443 US7851441B2 (en) | 2004-10-29 | 2005-10-27 | Water-soluble elastin, process for producing same, and food and medicine containing same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004316584 | 2004-10-29 | ||
JP2004-316584 | 2004-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006046626A1 true WO2006046626A1 (ja) | 2006-05-04 |
Family
ID=36227868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/019751 WO2006046626A1 (ja) | 2004-10-29 | 2005-10-27 | 水溶性エラスチンとその製造方法及びそれを含む食品と医薬 |
Country Status (3)
Country | Link |
---|---|
US (1) | US7851441B2 (ja) |
JP (1) | JP4078431B2 (ja) |
WO (1) | WO2006046626A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011155565A1 (ja) * | 2010-06-10 | 2011-12-15 | 国立大学法人九州工業大学 | 可逆的な性質を示す温度応答性シートとそれを用いた細胞シートの製造方法 |
JP2012056879A (ja) * | 2010-09-08 | 2012-03-22 | Kyushu Institute Of Technology | アンジオテンシン変換酵素阻害剤およびその用途 |
JP5060653B2 (ja) * | 2009-03-27 | 2012-10-31 | 株式会社マルハニチロ食品 | エラスチン及びコラーゲンを用いた架橋物及びその用途 |
JP2014091694A (ja) * | 2012-11-02 | 2014-05-19 | Mie Univ | 水溶性フィブリリン組成物による弾性線維増強法 |
CN104981456A (zh) * | 2013-02-01 | 2015-10-14 | 学校法人上智学院 | 锁链素、异锁链素以及它们的衍生物的制造方法 |
WO2016098816A1 (ja) * | 2014-12-17 | 2016-06-23 | 国立大学法人 九州工業大学 | 生体成分含有溶液の製造方法及び生体成分含有物 |
JP2019112357A (ja) * | 2017-12-25 | 2019-07-11 | 国立大学法人九州工業大学 | 水溶性エラスチン及びその製造方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102906109B (zh) * | 2010-02-19 | 2014-09-24 | 国立大学法人九州工业大学 | 化学修饰水溶性弹性蛋白、化学修饰水溶性弹性蛋白与胶原的混合凝胶以及它们的制造方法 |
US11478504B2 (en) | 2013-07-08 | 2022-10-25 | International Dehydrated Foods, Inc. | Compositions and methods for preventing/treating metabolic syndrome |
GB201711360D0 (en) | 2017-07-14 | 2017-08-30 | Raft Entpr Ltd | Tissue scaffold |
CA3073750A1 (en) * | 2017-09-28 | 2019-04-04 | International Dehydrated Foods, Inc. | Compositions and methods for preventing/treating metabolic syndrome |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2498452A2 (fr) * | 1981-01-28 | 1982-07-30 | Invap Etablissement | Compositions pharmaceutiques a base d'elastine soluble utilisables par voie interne |
WO2002096978A1 (fr) * | 2001-05-30 | 2002-12-05 | Keiichi Miyamoto | Elastine reticulee et son procede de production |
JP2004229611A (ja) * | 2003-01-31 | 2004-08-19 | J-Oil Mills Inc | 抗紫外線食品組成物 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2392674A1 (fr) | 1977-06-01 | 1978-12-29 | Invap Etablissement | Compositions pharmaceutiques a base d'elastine |
US4419288A (en) * | 1981-08-27 | 1983-12-06 | Seton Company | Elastin hydrolyzate |
JPS60181005A (ja) | 1984-02-28 | 1985-09-14 | Koken:Kk | 化粧用エラスチン |
JPS60258107A (ja) | 1984-06-01 | 1985-12-20 | Sansho Seiyaku Kk | 皮膚及び頭髪化粧料 |
JPH0630616B2 (ja) | 1988-08-24 | 1994-04-27 | 株式会社ニッピ | 水溶性エラスチンの製法及びコラーゲンとエラスチンを含む成型用組成物 |
JP2927076B2 (ja) | 1991-06-20 | 1999-07-28 | 味の素株式会社 | 新規タンパク食品素材 |
JP3687995B2 (ja) | 1994-07-22 | 2005-08-24 | 住友ベークライト株式会社 | 人工血管及びその製造方法 |
JP3573554B2 (ja) | 1995-12-27 | 2004-10-06 | 住友ベークライト株式会社 | 人工血管及びその製造方法 |
JP2002205913A (ja) | 2001-01-10 | 2002-07-23 | Ichimaru Pharcos Co Ltd | 化粧料組成物 |
JP2005013124A (ja) | 2003-06-27 | 2005-01-20 | Toyo Shinyaku:Kk | 美容効果を有する食品組成物 |
JP2005013123A (ja) | 2003-06-27 | 2005-01-20 | Toyo Shinyaku:Kk | 食品組成物 |
-
2005
- 2005-10-27 WO PCT/JP2005/019751 patent/WO2006046626A1/ja active Application Filing
- 2005-10-27 JP JP2006543232A patent/JP4078431B2/ja active Active
- 2005-10-27 US US11/666,443 patent/US7851441B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2498452A2 (fr) * | 1981-01-28 | 1982-07-30 | Invap Etablissement | Compositions pharmaceutiques a base d'elastine soluble utilisables par voie interne |
WO2002096978A1 (fr) * | 2001-05-30 | 2002-12-05 | Keiichi Miyamoto | Elastine reticulee et son procede de production |
JP2004229611A (ja) * | 2003-01-31 | 2004-08-19 | J-Oil Mills Inc | 抗紫外線食品組成物 |
Non-Patent Citations (3)
Title |
---|
"'Shin Seikagaku Jikken Koza 1 Tanpakushits u I-Bunri Seisei Seishitsu-'", KABUSHIKI KAISHA TOKYO KAGAKU DOJIN, XX, XX, 1 January 1990 (1990-01-01), XX, pages 143 - 152, XP002999840 * |
KIMURA YOSHIYUKI AND OKUDA HIROMICHI.: "Inhibitory effects of soluble elastin on intraplatelet free calcium concentration.", THROMBOSIS RES., vol. 52, no. 1, 1988, pages 61 - 64, XP002999839 * |
SEKIYA KEIZO AND OKUDA HIROCHIMI.: "Inhibitory action of soluble elastin on thromboxane B2 formation in blood platelets.", BIOCHIMICA ET BIOPHYSICA ACTA., vol. 797, no. 3, 1984, pages 348 - 353, XP002999838 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5060653B2 (ja) * | 2009-03-27 | 2012-10-31 | 株式会社マルハニチロ食品 | エラスチン及びコラーゲンを用いた架橋物及びその用途 |
JP5870408B2 (ja) * | 2010-06-10 | 2016-03-01 | 国立大学法人九州工業大学 | 可逆的な性質を示す温度応答性シートとそれを用いた細胞シートの製造方法 |
WO2011155565A1 (ja) * | 2010-06-10 | 2011-12-15 | 国立大学法人九州工業大学 | 可逆的な性質を示す温度応答性シートとそれを用いた細胞シートの製造方法 |
US9090869B2 (en) | 2010-06-10 | 2015-07-28 | Kyushu Institute Of Technology | Temperature responsive sheet that displays reversible properties and cell sheet production method using same |
JP2012056879A (ja) * | 2010-09-08 | 2012-03-22 | Kyushu Institute Of Technology | アンジオテンシン変換酵素阻害剤およびその用途 |
JP2014091694A (ja) * | 2012-11-02 | 2014-05-19 | Mie Univ | 水溶性フィブリリン組成物による弾性線維増強法 |
CN104981456A (zh) * | 2013-02-01 | 2015-10-14 | 学校法人上智学院 | 锁链素、异锁链素以及它们的衍生物的制造方法 |
JPWO2014119479A1 (ja) * | 2013-02-01 | 2017-01-26 | 学校法人上智学院 | デスモシン、イソデスモシン、およびその誘導体の製造方法 |
US9556119B2 (en) | 2013-02-01 | 2017-01-31 | Sophia School Corporation | Process for preparing desmosine, isodesmosine, and derivatives thereof |
WO2016098816A1 (ja) * | 2014-12-17 | 2016-06-23 | 国立大学法人 九州工業大学 | 生体成分含有溶液の製造方法及び生体成分含有物 |
JPWO2016098816A1 (ja) * | 2014-12-17 | 2017-09-28 | 国立大学法人九州工業大学 | 生体成分含有溶液の製造方法及び生体成分含有物 |
JP7051065B2 (ja) | 2014-12-17 | 2022-04-11 | 国立大学法人九州工業大学 | 生体成分含有溶液の製造方法及び生体成分含有溶液 |
JP2019112357A (ja) * | 2017-12-25 | 2019-07-11 | 国立大学法人九州工業大学 | 水溶性エラスチン及びその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
US7851441B2 (en) | 2010-12-14 |
JPWO2006046626A1 (ja) | 2008-08-07 |
JP4078431B2 (ja) | 2008-04-23 |
US20080096812A1 (en) | 2008-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006046626A1 (ja) | 水溶性エラスチンとその製造方法及びそれを含む食品と医薬 | |
JP4236850B2 (ja) | 魚類由来のコラーゲンペプチドの製造方法並びに該製造方法により得られた魚類由来のコラーゲンペプチドを含有する飲食品及び化粧品 | |
FR2715405A1 (fr) | Procédé pour l'élimination des prions dans des collagènes et collagènes ainsi obtenus. | |
EP2666779A1 (en) | Method for mass preparation of proteoglycan | |
JP2017114868A (ja) | 胎盤由来成分を含有するシワ改善用組成物 | |
JP2015042688A (ja) | 血管改善剤 | |
JP2007045722A (ja) | 水溶性エラスチンとそれを含む食品及び医薬 | |
JP5590704B2 (ja) | 魚類由来の水溶性エラスチンを有効成分とする血小板凝集阻害剤 | |
JP2003299497A (ja) | ムコ多糖類及びその製造方法 | |
JPS62502833A (ja) | ヒアルロン酸の製法 | |
JPH08143442A (ja) | 皮膚外用剤及びその製造法 | |
JP2011225495A (ja) | 血管内皮細胞保護剤ならびにこれを含む医薬組成物、食品および飼料 | |
US5897881A (en) | Hard tissue intactly dissolved materials and method for producing the same | |
JP6324733B2 (ja) | コラーゲンの三重螺旋構造安定化剤 | |
JP3521238B2 (ja) | 水酸化比の高いi型コラーゲン | |
JP2004049124A (ja) | 大豆7sたん白含有タブレット | |
DE60209793T2 (de) | Modifierte methioninereiche nahrungsmittel und verfahren zu deren herstellung | |
CN113603768B (zh) | 一种鱼源胶原蛋白的制备方法 | |
JP4334189B2 (ja) | Age生成阻害剤 | |
JP3518778B2 (ja) | ポリアミンの調製方法 | |
JP2009219422A (ja) | 水溶性エラスチン混合物とその製造方法並びにそれを含む機能性食品 | |
JP6712014B2 (ja) | 水溶性エラスチン | |
JP2001112419A (ja) | Ii型コラーゲンの製造方法 | |
JP7051065B2 (ja) | 生体成分含有溶液の製造方法及び生体成分含有溶液 | |
JPH067188A (ja) | ペプチド含有食品製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MD MG MK MN MW MX MZ NA NG NO NZ OM PG PH PL PT RO RU SC SD SG SK SL SM SY TJ TM TN TR TT TZ UG US UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IS IT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW MR NE SN TD TG |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006543232 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11666443 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05799353 Country of ref document: EP Kind code of ref document: A1 |
|
WWP | Wipo information: published in national office |
Ref document number: 11666443 Country of ref document: US |